|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 92.78 USD | -0.50% |
|
+7.41% | -6.98% |
| 07-30 | Celcuity Announces FDA Approval And NCCN Guidelines Inclusion For REVTORPYK In Combination With Fulvestrant With Or Without Palbociclib | CI |
| 07-15 | Celcuity Inc. - Special Call |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| CELCUITY INC. | Bio Therapeutic Drugs | -0.50% | +7.41% | -6.98% | +102.22% | +344.99% | 4.52B |  | |  |
- Stock Market
- Stocks
- CELC Stock
- Charts Celcuity Inc.
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
